Division of Laboratory Medicine, Asia University Hospital, Asia University, Taichung, Taiwan.
Institute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung, Taiwan.
Adv Clin Chem. 2023;115:63-80. doi: 10.1016/bs.acc.2023.03.001. Epub 2023 May 8.
Cardiovascular disease (CVD) is prevalent in patients with chronic kidney disease (CKD) and it is responsible for approximately half of all CKD-related deaths. CVDs are the primary cause of death in hemodialysis patients due to major adverse cardiovascular events. Therefore, better approaches for differentiating chronic hemodialysis patients at higher cardiovascular risk will help physicians improve clinical outcomes. Hence, there is an urgent need to discover feasible and reliable cardiac biomarkers to improve diagnostic accuracy, reflect myocardial injury, and identify high-risk patients. Numerous biomarkers that have significant prognostic value with respect to adverse CVD outcomes in the setting of mild to severe CKD have been identified. Therefore, a better understanding of the positive clinical impact of cardiac biomarkers on CVD patient outcomes is an important step toward prevention and improving treatment in the future. In this review, we address the relationship between cardiovascular biomarkers and CKD treatment strategies to elucidate the underlying importance of these biomarkers to patient outcomes.
心血管疾病（CVD）在慢性肾脏病（CKD）患者中较为常见，约占所有 CKD 相关死亡人数的一半。由于主要不良心血管事件，CVD 是血液透析患者死亡的主要原因。因此，更好的方法来区分具有更高心血管风险的慢性血液透析患者将有助于医生改善临床结局。因此，迫切需要发现可行和可靠的心脏生物标志物，以提高诊断准确性、反映心肌损伤，并识别高危患者。已经发现了许多在轻度至重度 CKD 环境中对不良 CVD 结局具有重要预后价值的生物标志物。因此，更好地了解心脏生物标志物对 CVD 患者结局的积极临床影响是未来预防和改善治疗的重要步骤。在这篇综述中，我们探讨了心血管生物标志物与 CKD 治疗策略之间的关系，以阐明这些生物标志物对患者结局的重要性。
